JPWO2023059596A5 - - Google Patents
Info
- Publication number
- JPWO2023059596A5 JPWO2023059596A5 JP2024520700A JP2024520700A JPWO2023059596A5 JP WO2023059596 A5 JPWO2023059596 A5 JP WO2023059596A5 JP 2024520700 A JP2024520700 A JP 2024520700A JP 2024520700 A JP2024520700 A JP 2024520700A JP WO2023059596 A5 JPWO2023059596 A5 JP WO2023059596A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- kras
- pharmaceutical composition
- pan
- erbb family
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163252534P | 2021-10-05 | 2021-10-05 | |
| US63/252,534 | 2021-10-05 | ||
| PCT/US2022/045621 WO2023059596A1 (en) | 2021-10-05 | 2022-10-04 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH Pan ErbB FAMILY INHIBITORS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024537136A JP2024537136A (ja) | 2024-10-10 |
| JPWO2023059596A5 true JPWO2023059596A5 (https=) | 2025-10-10 |
| JP2024537136A5 JP2024537136A5 (https=) | 2025-10-10 |
Family
ID=85803674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024520700A Pending JP2024537136A (ja) | 2021-10-05 | 2022-10-04 | ＫＲＡＳ Ｇ１２Ｄ阻害剤と汎ＥｒｂＢファミリー阻害剤との併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240408099A1 (https=) |
| EP (1) | EP4412717A4 (https=) |
| JP (1) | JP2024537136A (https=) |
| KR (1) | KR20240089340A (https=) |
| CN (1) | CN118369119A (https=) |
| AU (1) | AU2022359880A1 (https=) |
| CA (1) | CA3233567A1 (https=) |
| IL (1) | IL311835A (https=) |
| MX (1) | MX2024004216A (https=) |
| WO (1) | WO2023059596A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024543879A (ja) * | 2021-11-24 | 2024-11-26 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｋｒａｓ変異型タンパク質の小分子阻害剤 |
| WO2025034919A1 (en) * | 2023-08-08 | 2025-02-13 | Quanta Therapeutics, Inc. | Combination therapies with kras modulators |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250114339A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor |
| AU2024357850A1 (en) | 2023-10-09 | 2026-04-23 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2026060400A1 (en) * | 2024-09-16 | 2026-03-19 | Quanta Therapeutics, Inc. | Combination therapies with kras modulators |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013234767B2 (en) | 2012-03-19 | 2017-02-23 | Merck Patent Gmbh | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds |
| CA3112043A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| WO2021041671A1 (en) | 2019-08-29 | 2021-03-04 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| WO2023284730A1 (en) * | 2021-07-14 | 2023-01-19 | Nikang Therapeutics, Inc. | Alkylidene derivatives as kras inhibitors |
-
2022
- 2022-10-04 CA CA3233567A patent/CA3233567A1/en active Pending
- 2022-10-04 CN CN202280077622.7A patent/CN118369119A/zh active Pending
- 2022-10-04 KR KR1020247014965A patent/KR20240089340A/ko active Pending
- 2022-10-04 WO PCT/US2022/045621 patent/WO2023059596A1/en not_active Ceased
- 2022-10-04 JP JP2024520700A patent/JP2024537136A/ja active Pending
- 2022-10-04 MX MX2024004216A patent/MX2024004216A/es unknown
- 2022-10-04 EP EP22879174.5A patent/EP4412717A4/en active Pending
- 2022-10-04 US US18/694,867 patent/US20240408099A1/en active Pending
- 2022-10-04 AU AU2022359880A patent/AU2022359880A1/en active Pending
- 2022-10-04 IL IL311835A patent/IL311835A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025000632A5 (https=) | ||
| JP2025000629A5 (https=) | ||
| JP2025000630A5 (https=) | ||
| JPWO2023059597A5 (https=) | ||
| FI3849537T3 (fi) | Yhdistelmäterapioita | |
| JPWO2021061749A5 (https=) | ||
| CN102612365B (zh) | 用于强化dna损伤剂的检查点激酶1抑制剂 | |
| IL311834A (en) | Combinations of KRAS G12D inhibitors with PI3KA inhibitors and therapeutic methods | |
| US20260097013A1 (en) | Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone | |
| IL311863A (en) | Combinations of KRAS G12D inhibitors and irinotecan and therapeutic methods | |
| JPWO2020118066A5 (https=) | ||
| IL315645A (en) | Combination therapies comprising a sos1 inhibitor and an egfr inhibitor | |
| JPWO2023059596A5 (https=) | ||
| US20140045782A1 (en) | Method of treatment using checkpoint kinase 1 inhibitors | |
| JPWO2020055755A5 (https=) | ||
| JP2009506054A5 (https=) | ||
| JP2015528469A (ja) | 前立腺の治療のための薬物送達システム及び方法 | |
| JPWO2020055760A5 (https=) | ||
| JPWO2023059594A5 (https=) | ||
| NO20092581L (no) | Kombinasjonsterapi av lavere urinveislidelser med alfa2delta-ligander og NSAID'er | |
| JPWO2023059598A5 (https=) | ||
| WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| JPWO2023059600A5 (https=) | ||
| JPWO2022251193A5 (https=) | ||
| IL315648A (en) | Combination therapy of SOS1 inhibitor and MEK inhibitor |